December 13th 2022
September 27th 2022
Aaron T. Gerds, MD, MS, discusses the phase 3 VERIFY trial examining rusfertide in patients with polycythemia vera.
January 27th 2022
Aaron T. Gerds, MD, MS, discusses emerging agents in myelofibrosis.
January 17th 2022
Aaron T. Gerds, MD, MS, discusses the rationale for the real-world REVEAL study in polycythemia vera.
September 20th 2021
Expert hematologist/oncologists review the use of pacritinib for the treatment of myelofibrosis, as seen in the PERSIST-1 and PERSIST-2 trials.
Aaron Gerds, MD, MS; and Srdan Verstovsek, MD, PhD, share insights on the impact of pathways, including JAK-STAT, on myelofibrosis disease progression and discuss considerations for the use of JAK inhibitors.
September 13th 2021
Hematology/oncology experts review their approach to monitoring treatment response in myelofibrosis (MF) and when they would consider switching therapies.
Aaron Gerds, MD, MS; and Srdan Verstovsek, MD, PhD, share insights on the importance of allele burden in myelofibrosis (MF) and how cytopenias can limit treatment options for patients with myelofibrosis.
September 7th 2021
Experts in hematology/oncology comment on challenges in treating patients with myelofibrosis.
Srdan Verstovsek, MD, PhD, and Aaron Gerds, MD, MS, review key updates to NCCN guidelines for primary myelofibrosis and discuss treatment options for the disease.
August 30th 2021
Aaron Gerds, MD, MS, provides insight on determining low- vs high-risk primary myelofibrosis, the role of molecular status on treatment, and his approach toward symptom burden assessment.
Srdan Verstovsek, MD, PhD, describes the classic signs and symptoms of primary myelofibrosis (PMF), along with goals of therapy.